Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region
A mid-size pharmaceutical company based in the United States (US) and Europe (EU) was developing a COVID-19 vaccine using a prioritized protocol with an extremely aggressive timeline. In the race to develop a successful vaccine, they needed a partner that had the network, capabilities, and expertise to coordinate all project activities and provide solutions to get to market faster and more importantly, further accelerate the speed of providing product to the patient.
Download the case study to learn more.